Furthermore, treatments for each condition often intersect, with cardiotoxic effects being a notable concern in cancer therapy, such as the use of anthracyclines and HER2 inhibitors in oncology that necessitate careful cardiovascular monitoring. The gene discussed is ERBB2; the disease is cancer.